Cerevance has said it plans to move on to ... Roche/Prothena and AbbVie. Inhibikase Therapeutics is meanwhile running early-stage trials of a c-Abl inhibitor and Denali Therapeutics/Biogen are ...

UK-based pharmaceutical company Cerevance has announced positive outcomes from its Phase I trial of CVN293, a drug candidate ...

Takeda and venture capital group Lightstone Ventures have launched Cerevance, a neuroscience company focused on discovering and developing novel therapeutics for neurological and psychiatric ...

The symposium opened with a keynote address by Brad Margus, a biotech entrepreneur, innovator and advocate for neurodegenerative disease research and co-founder of Cerevance and Board Chair of ...